NICOLE VINES: Open Payments
NPI 1235614439 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,233 in 48 payments from 23 companies in 2025. Trend: 2023 $806 · 2024 $860 · 2025 $1,233
Food & beverage: $1,233
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 4 | $340 |
| AstraZeneca Pharmaceuticals LP | 9 | $147 |
| Novartis Pharmaceuticals Corporation | 5 | $99 |
| Incyte Corporation | 4 | $88 |
| Genmab U.S., Inc. | 2 | $55 |
| Genentech USA, Inc. | 2 | $50 |
| BeOne Medicines USA, Inc. | 2 | $44 |
| Merck Sharp & Dohme LLC | 2 | $42 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $38 |
| Gilead Sciences, Inc. | 2 | $38 |
Products named: RYBREVANT, KISQALI, JAKAFI, Epkinly, ENHERTU, BRUKINSA, KEYTRUDA, Nubeqa.
Industry payments across DE — which companies pay providers there.
